Document is current
Any future updates will be listed below
-
Authors
Adachi, Masahiro https://orcid.org/0000-0001-6489-446X
Aoyama, Naoki
Kojima, Motohiro https://orcid.org/0000-0002-6150-6545
Sakamoto, Naoya https://orcid.org/0000-0001-6273-0189
Miyazaki, Saori
Taki, Tetsuro
Watanabe, Reiko
Matsuura, Kazuto
Kotani, Daisuke https://orcid.org/0000-0002-4196-555X
Kojima, Takashi
Fujita, Takeo https://orcid.org/0000-0002-6098-9813
Tabuchi, Keiji
Ishii, Genichiro https://orcid.org/0000-0001-8637-3323
Sakashita, Shingo https://orcid.org/0000-0003-1133-3313
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (KAKENHI JP20K22859 and JP21K06899)
- License Information
-
More Information
Article History
Received: 4 August 2022
Accepted: 16 September 2022
First Online: 6 October 2022
Declarations
:
: Daisuke Kotani received research funding from Ono Pharmaceutical Co., MSD K.K., Novartis, Servier, Janssen, IQVIA, Syneoshealth, Cimic, and Cimicshiftzero. Takashi Kojima received research funding from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, BeiGene Ltd., EPS Corporation., MSD K.K., Amgen Inc., SHIONOGI & Co., Ltd., CHUGAI PHARMACEUTICAL CO.,LTD., TAIHO PHARMACEUTICAL CO., LTD., Parexel International, Merck Biopharma Co., Ltd. Genichiro Ishii received research funding from DAIICHI SANKYO, INC., ONO Pharmaceutical CO., LTD., Noile-Immune Biotech, Inc., Takeda Pharmaceutical Company Limited, Sumitomo Dainippon Pharma Co., Ltd., and Nihon Medi-Physics Co., Ltd. Other authors have no relevant financial or non-financial interests to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the institutional review board of the National Cancer Center Hospital East (October 5, 2020/approval number 2020-292).
: Informed consent was obtained from all individual participants included in the study
